Clonal evolution and molecular profiling of recurrent maxillary ameloblastoma with lung metastasis harboring SMO and PIK3CA mutations

Most people think of cancer as a disease that spreads from one part of the body to another, growing more dangerous and harder to treat with every step. But there is a rare group of tumors that behave differently. These growths, which arise from the cells that form teeth, are usually considered benign, meaning they do not spread to distant organs in the way typical cancers do. Yet, in a small number of cases, these tumors can break away from their original site and travel to the lungs. For decades, doctors have struggled to understand how this happens. Is the tumor changing its nature as it spreads, becoming more aggressive? Or does it carry the same genetic instructions from the start, simply moving to a new location? Answering this question is vital because it determines how doctors should treat patients. If the tumor changes, the treatment might need to change too. If it stays the same, the focus might be on targeting the specific genetic errors that started the journey.

At Shizuoka Cancer Center in Japan, a team of researchers decided to look closely at a patient who had been fighting a recurring tumor in the upper jaw for many years. This patient had undergone five separate surgeries to remove the tumor from the maxilla, the bone that holds the upper teeth. Despite these efforts, the tumor kept coming back. Eventually, the cancer spread to both lungs, appearing as nodules in the upper and lower sections. The medical team removed the recurrent tumor from the jaw and the nodules from the lungs, collecting tissue samples from each site. Their goal was to read the genetic code of the cells in these different locations to see if they were related and to identify the specific errors driving the disease. They used a powerful tool that scans hundreds of genes at once, looking for the tiny spelling mistakes in the DNA that can cause cells to grow out of control.

When the researchers examined the tissue under a microscope, they saw that the tumor in the jaw had become quite active. The cells showed signs of stress and rapid division, with many of them dividing at the same time. However, the cells in the lung nodules looked slightly different; they were less chaotic and divided more slowly. This difference in appearance raised a question: were the lung tumors a new, more dangerous version of the disease, or were they the same old enemy just in a new place? To find the answer, the scientists turned to the genetic data. They found that the tumor in the jaw and the tumors in the lungs shared two identical, critical genetic errors. One error was in a gene called SMO, which acts like a switch for a signaling pathway that tells cells when to grow. The other error was in a gene called PIK3CA, which is part of a different pathway that helps cells survive and multiply. These two mistakes were present in the jaw tumor and in both lung nodules, exactly the same way.

The presence of these shared errors provided a clear link between the different parts of the body. It showed that the lung tumors were not a new, unrelated disease that had developed on its own. Instead, they were descendants of the original tumor in the jaw, carrying the same genetic instructions that allowed them to survive and spread. The researchers also noticed that the lung tumors had a few extra genetic changes that were not found in the jaw, suggesting that as the tumor traveled and settled in the lungs, it picked up a few new traits. But the core drivers of the disease, the SMO and PIK3CA errors, remained constant. This finding is significant because it suggests that the tumor did not fundamentally change its nature to become metastatic; it simply carried its original genetic blueprint with it.

This discovery helps clarify the nature of these rare, spreading tumors. It supports the idea that the genetic errors found in the jaw were the starting point for the entire disease, including the spread to the lungs. The researchers noted that while the tumor in the jaw looked more aggressive under the microscope, the genetic evidence showed that the lung tumors were still part of the same family. This distinction is important for understanding how these tumors evolve. It also points toward a potential way to treat them. Since the same genetic errors are present in both the jaw and the lungs, a drug designed to block those specific errors could theoretically work on all the tumors at once. While the researchers did not test a treatment in this study, their findings suggest that targeting these specific genetic switches might be a viable strategy for patients with this difficult condition. The study confirms that even when a tumor spreads to a distant organ, it often retains the molecular fingerprint of its origin, offering a clear target for future medical interventions.